Want to see CMPS full AI Analyst Report?
Top Page
COMPASS Pathways
(NASDAQ:CMPS)
Select Model
Select Model
Rating:60Neutral
Price Target:
$13.50
▲(102.70% Upside)
Action:Reiterated
Date:07/08/26
Overall score reflects a strong catalyst-driven story tempered by weak current fundamentals: persistent losses and heavy cash burn are the biggest drag. Offsetting factors include constructive technical momentum and positive regulatory/clinical progress (rolling NDA, priority voucher, and supportive Phase 3 durability data), while valuation remains difficult to justify on earnings given ongoing unprofitability.
Positive Factors
Phase III durability & efficacy
Two large, well-controlled pivotal trials (005 and 006) with ~1,000+ patients and blinded 26-week follow-up demonstrate reproducible rapid onset and durable benefit. Durable efficacy in a severe, chronic TRD cohort strengthens the clinical value proposition, improves regulatory credibility and underpins longer-term payer conversations and adoption assumptions.
Negative Factors
Pre-revenue & persistent cash burn
The company remains pre-revenue with large, recurring operating losses and deeply negative operating/free cash flow. Persistent cash burn implies ongoing dependence on external financing until commercial revenues materialize, which can dilute shareholders and constrain strategic flexibility over the medium term if reimbursement and launch timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase III durability & efficacy
Two large, well-controlled pivotal trials (005 and 006) with ~1,000+ patients and blinded 26-week follow-up demonstrate reproducible rapid onset and durable benefit. Durable efficacy in a severe, chronic TRD cohort strengthens the clinical value proposition, improves regulatory credibility and underpins longer-term payer conversations and adoption assumptions.
Read all positive factors
COMPASS Pathways (CMPS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.84B
Dividend YieldN/A
Average Volume (3M)4.04M
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue GrowthN/A
EPS Growth-9.94%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume4,807,621
30 Day Avg. Volume4,040,313
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.87
Forecast
1Y Price Target
$24.43Price Target Upside266.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$2.31M
COMPASS Pathways Business Overview & Revenue Model
Company Description
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP3...
How the Company Makes Money
null...
COMPASS Pathways Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call emphasized strong clinical momentum (positive Phase III results, >1,000 patients in the program), concrete regulatory progress (rolling NDA alignment and a Commissioner's National Priority Voucher) and active commercial preparedness (experienced hires, CPT code groundwork, VA engagement and state-level rescheduling progress). These material positives are balanced against remaining execution and timing risks — notably pending 26-week data to complete the submission, CPT valuation and RUC/CMS steps, DEA/federal rescheduling sequencing, REMS and payer negotiation uncertainties, and competitive dynamics. Overall, the company presented multiple compelling strengths and a clear launch plan while acknowledging the remaining regulatory, reimbursement and operational work required before broad patient access.Positive Updates
Positive Phase III Results & Robust Clinical Dataset
COMP360 produced positive data from two pivotal Phase III trials (005 and 006) with the program enrolling over 1,000 patients across late-stage studies and over 800 participants from the two pivotal Phase III trials. Trials were blinded for an unprecedented 26 weeks for psychiatry, supporting claims of clinically meaningful, rapid onset and extended durability. Reported response metrics included ~25% clinically meaningful response from a single administration (005) and ~40% with the addition of a second fixed dose (006). Safety, preclinical toxicology and CMC data cited as comprehensive and supportive for NDA.
Negative Updates
Regulatory Timing & Uncertainty (AdCom & DEA Sequencing)
Key regulatory elements remain uncertain: whether the FDA will convene an advisory committee (AdCom) is unknown and could affect timing. Although a CNPV was awarded, the formal accelerated review clock only begins after the final NDA submission and DEA rescheduling remains a sequential process that could still introduce timing variability despite executive order intent.
Read all updates
Q1-2026 Updates
Positive
Negative
Positive Phase III Results & Robust Clinical Dataset
COMP360 produced positive data from two pivotal Phase III trials (005 and 006) with the program enrolling over 1,000 patients across late-stage studies and over 800 participants from the two pivotal Phase III trials. Trials were blinded for an unprecedented 26 weeks for psychiatry, supporting claims of clinically meaningful, rapid onset and extended durability. Reported response metrics included ~25% clinically meaningful response from a single administration (005) and ~40% with the addition of a second fixed dose (006). Safety, preclinical toxicology and CMC data cited as comprehensive and supportive for NDA.
Read all positive updates
Company Guidance
COMPASS reiterated that it is on a rolling NDA submission with the FDA, expects Part B (26‑week) data from COMP006 in early Q3 2026 (the final dataset to complete the submission), is targeting being launch‑ready by the end of 2026, and—having been awarded a Commissioner’s National Priority Voucher—could see an ultra‑accelerated FDA review of ~1–2 months after final submission; the company says it has run >1,000 patients in the program (including >800 across two pivotal Phase III trials with unprecedented 26‑week blinded follow‑up and 52‑week data running in parallel), reported a 25% clinically meaningful response after a single dose in 005 and 40% with a second fixed dose in 006, and has cash runway into 2028 following Q1 financing/warrant exercises; commercial and access metrics highlighted include ~4 million U.S. TRD patients, ~13 million Americans with PTSD, Spravato’s ~ $3B projected revenue by 2027 while treating <2% of TRD as of 2025, ~7,500 interventional clinics in market, CPT Category III codes billable by the hour (pathway to Category I), buy‑and‑bill penetration of ~35–45%, nearly 90% of the U.S. population in states intending to reschedule within 30 days of federal action, and expectations that REMS and DEA rescheduling work will be coordinated to enable rapid patient access.COMPASS Pathways Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -176.60M | -285.60M | -148.82M | -115.24M | -90.77M | -71.37M |
| Net Income | -178.80M | -287.86M | -155.12M | -118.46M | -91.50M | -71.74M |
Balance Sheet | ||||||
| Total Assets | 531.74M | 210.35M | 213.67M | 275.99M | 197.29M | 300.90M |
| Cash, Cash Equivalents and Short-Term Investments | 466.01M | 149.61M | 165.08M | 220.20M | 143.21M | 273.24M |
| Total Debt | 2.83M | 20.93M | 32.19M | 33.05M | 1.93M | 3.61M |
| Total Liabilities | 205.05M | 263.20M | 58.97M | 50.24M | 16.01M | 16.49M |
| Stockholders Equity | 326.69M | -52.85M | 154.69M | 225.74M | 181.28M | 284.41M |
Cash Flow | ||||||
| Free Cash Flow | -159.52M | -157.24M | -119.19M | -97.44M | -106.05M | -68.08M |
| Operating Cash Flow | -159.52M | -157.24M | -119.19M | -97.38M | -105.45M | -67.75M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -64.00K | -596.00K | -334.00K |
| Financing Cash Flow | 362.81M | 140.71M | 63.82M | 173.83M | 1.04M | 156.65M |
COMPASS Pathways Technical Analysis
Positive
6.66
Price Trends
11.79
Positive
9.29
Positive
7.79
Positive
Market Momentum
0.57
Positive
56.44
Neutral
56.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPS, the sentiment is Positive. The current price of 6.66 is below the 20-day moving average (MA) of 13.03, below the 50-day MA of 11.79, and below the 200-day MA of 7.79, indicating a bullish trend. The MACD of 0.57 indicates Positive momentum. The RSI at 56.44 is Neutral, neither overbought nor oversold. The STOCH value of 56.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMPS.
COMPASS Pathways Risk Analysis
COMPASS Pathways disclosed 100 risk factors in its most recent earnings report. COMPASS Pathways reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
COMPASS Pathways Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $876.09M | 1,108.51 | 1.03% | ― | 22.64% | -58.05% | |
60 Neutral | $1.84B | -6.28 | -151.02% | ― | ― | -9.94% | |
59 Neutral | $1.56B | -37.80 | -9.20% | ― | 14.13% | 62.92% | |
59 Neutral | $427.09M | -4.33 | -27.10% | ― | -20.37% | -479.68% | |
58 Neutral | $1.92B | -4.95 | -146.01% | ― | -2.82% | -45.70% | |
56 Neutral | $588.90M | -16.67 | 326.77% | ― | 35.37% | 46.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CMPS
COMPASS Pathways
13.64
9.93
267.65%
CCRN
Cross Country Healthcare
13.22
1.14
9.44%
TOI
Oncology Institute
5.89
2.68
83.49%
TALK
Talkspace
5.23
2.66
103.50%
INNV
InnovAge Holding
11.52
7.21
167.29%
AGL
Agilon Health
114.85
58.60
104.18%
COMPASS Pathways Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Compass Pathways reports positive Phase 3 depression results
Positive
Jul 7, 2026
On July 7, 2026, Compass Pathways reported 26-week results from Part B of its second Phase 3 COMP006 trial of COMP360 psilocybin in treatment-resistant depression, involving nearly 600 patients with highly chronic illness. The data confirmed rapid...
Executive/Board ChangesDividendsFinancial DisclosuresShareholder Meetings
COMPASS Pathways Shareholders Approve 2026 AGM Proposals, Board Changes
Positive
May 28, 2026
COMPASS Pathways held its 2026 Annual General Meeting of Shareholders on May 27, 2026, with 58,880,058 ordinary shares represented in person or by proxy and ADSs without voting instructions classified as broker non-votes. Shareholders re-elected d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.